Quebec Rejects Reimbursement for Wegovy Obesity Drug

–wp:paragraph

Quebec’s government has reaffirmed its decision not to cover the cost of Wegovy, a prescription medication used for chronic weight management, under its public drug insurance plan. The stance comes despite growing demand for the drug and ongoing debates about its role in addressing obesity as a chronic condition. Officials cited the medication’s high monthly cost — estimated between $300 and $500 — as a primary factor in maintaining the current coverage policy.

–wp:paragraph

Wegovy, known generically as semaglutide, is approved by Health Canada for long-term weight management in adults with obesity or overweight who have at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol. It works by mimicking a hormone that targets areas of the brain involved in regulating appetite and food intake. Clinical trials have shown that, when combined with lifestyle changes, Wegovy can lead to significant weight loss, with many participants losing 15% or more of their body weight over 68 weeks.

–wp:paragraph

The drug’s manufacturer, Novo Nordisk, has priced Wegovy at approximately $329 per month in Canada, though out-of-pocket costs can vary depending on pharmacy fees, and dosage. In Quebec, the Régie de l’assurance maladie du Québec (RAMQ) evaluates medications for public coverage based on clinical effectiveness, cost-effectiveness, and budget impact. In previous assessments, RAMQ has determined that while Wegovy shows efficacy, its high cost relative to other available interventions does not meet the threshold for public reimbursement under current criteria.

–wp:paragraph

Public health experts in Quebec have expressed mixed views on the decision. Some argue that excluding effective weight-loss medications from public coverage exacerbates health inequities, particularly for individuals with obesity-related conditions who may lack the financial means to pay out of pocket. Others emphasize the need for caution, noting that long-term data on the safety and societal cost-benefit of widespread semaglutide use are still evolving. Concerns have also been raised about potential overreliance on pharmacological solutions without sufficient investment in preventive care, nutrition programs, and accessible physical activity initiatives.

–wp:paragraph

Obesity affects nearly one in four adults in Quebec, according to recent data from the Institut de la statistique du Québec. The condition is linked to increased risks of cardiovascular disease, type 2 diabetes, certain cancers, and reduced life expectancy. While lifestyle modification remains the cornerstone of obesity management, many patients struggle to achieve and sustain weight loss through diet and exercise alone, prompting interest in medical interventions like Wegovy.

–wp:paragraph

Internationally, approaches to covering weight-loss medications vary. In the United States, some state Medicaid programs and private insurers now cover semaglutide for obesity under specific criteria, though prior authorization requirements are common. In Europe, national health systems such as those in the United Kingdom and Germany have begun evaluating semaglutide for broader reimbursement, often tying coverage to participation in structured weight-management programs.

–wp:paragraph

Quebec officials have not indicated plans to revisit the coverage decision in the near term. Any future reassessment would likely depend on updated cost-effectiveness analyses, potential price reductions, or new clinical evidence demonstrating broader public health benefits. For now, patients seeking Wegovy must cover the full cost privately or rely on private insurance plans that may offer partial reimbursement.